FDA-APPROVED PRODUCT THERAPY AREAS

FDA-approved Product

Therapy Areas

Sanofi has approved therapies for the following cancer types:

Blood: relapsed and/or refractory multiple myeloma (MM)
Prostate: metastatic castration-resistant prostate cancer (mCRPC)

Sanofi is also focused on hyperuricemia related to tumor lysis syndrome (TLS).

Educational Resources

General

Time to Screen: Information on Early Cancer Detection
TimeToScreen.org encourages and reminds people to take control of their health by getting recommended cancer screenings. The campaign is led by two national, non-profit organizations, Community Oncology Alliance (COA) and CancerCare.

https://timetoscreen.org/

Multiple Myeloma

Multiple Myeloma: Disease Overview
A presentation providing an overview of MM, including epidemiology, pathogenesis, diagnosis, staging and risk stratification, and response to therapy, including definitions and response criteria from the International Myeloma Working Group (IMWG). The presentation highlights minimal residual disease as an important prognostic factor in MM. There is also a brief introduction to the patient perspective.

Current Disease State of Multiple Myeloma
A two-minute video overview of the current disease state of newly diagnosed multiple myeloma, including epidemiology information, disease trajectory, survival outcomes, and transplant ineligibility.

High-risk Cytogenetic Abnormalities in Multiple Myeloma
An infographic providing an overview of cytogenetic abnormalities that confer high risk disease in multiple myeloma, including impact on management of these high risk multiple myeloma patients.

Chromosome 1q Abnormalities in Multiple Myeloma
One in a series of PDFs that provide education on relevant topics in MM. This edition focuses on chromosome 1q abnormalities, their implications for risk prediction, and the available guidance on treatment for this subpopulation.

Minimal Residual Disease in Multiple Myeloma
One in a series of PDFs that provide education on relevant topics in MM. This edition focuses on minimal residual disease (MRD), and includes an overview of MRD and the impact of achieving early and sustained MRD negativity on patient prognosis and outcomes.

Coombs Testing in Multiple Myeloma
One in a series of PDFs that provide education on relevant topics in MM. This edition focuses on Coombs testing, and includes an overview of the clinical impact of anti-CD38 interference in Coombs testing and the clinical management of anti-CD38 interference.

Renal Impairment in Multiple Myeloma (Infographic)
An infographic providing an overview of renal manifestations of multiple myeloma, including impact on patient management.

Unmet Needs in Lenalidomide-Refractory Multiple Myeloma
One in a series of PDFs that provide education on relevant topics in MM. This edition focuses on the challenge of lenalidomide-refractory disease in relapsed/refractory MM and the unmet need in this difficult to treat patient population.

Transplant Considerations in Multiple Myeloma
An infographic providing information on transplant considerations in patients with newly diagnosed multiple myeloma, including the shared decision-making process and patient-related factors.